Nicotine Dependence Pharmacogenetics: Role of Genetic Variation in Nicotine-Metabolizing Enzymes

Anticipating Clinical Integration of Pharmacogenetic Treatment Strategies for Addiction: Are Primary Care Physicians Ready?

(2008) AE Shields et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Toward Personalized Therapy for Smoking Cessation: A Randomized Placebo-controlled Trial of Bupropion

(2008) F Patterson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical Pharmacology of Nicotine: Implications for Understanding, Preventing, and Treating Tobacco Addiction

(2008) NL Benowitz   CLINICAL PHARMACOLOGY & THERAPEUTICS

Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent

(2008) Jill C. Mwenifumbo et al.   HUMAN MUTATION

A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent

(2008) Man Ki Ho et al.   Pharmacogenetics and Genomics

Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment

(2008) D F Heitjan et al.   PHARMACOGENOMICS JOURNAL

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial

(2008) H-J Aubin et al.   THORAX